{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:10:29Z","timestamp":1790359829362,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005688","name":"Graduate School, University of Texas, Austin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejmech.2019.111885","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T12:56:25Z","timestamp":1573736185000},"page":"111885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-8725","authenticated-orcid":false,"given":"Tamer S.","family":"Kaoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa M.","family":"Mohassab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina X.","family":"Van Ravenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-7124","authenticated-orcid":false,"given":"Dalia","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Dalby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejmech.2019.111885_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/0003-4819-118-8-199304150-00011","article-title":"Biological basis for cancer treatment","volume":"118","author":"Chabner","year":"1993","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2019.111885_bib2","first-page":"1481","article-title":"Melanoma: molecular pathogenesis and emerging target therapies (Review)","volume":"34","author":"Russo","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2019.111885_bib3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2013.32","article-title":"Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas","volume":"133","author":"Liu","year":"2013","journal-title":"J.\u00a0Investig. Dermatol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","article-title":"Strategies and approaches of targeting STAT3 for cancer treatment","volume":"11","author":"Furtek","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/cancers6020926","article-title":"Transcription factor STAT3 as a novel molecular target for cancer prevention","volume":"6","author":"Xiong","year":"2014","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","article-title":"Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation","volume":"82","author":"Wen","year":"1995","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.ejmech.2019.111885_bib7","first-page":"5059","article-title":"Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in\u00a0vivo","volume":"59","author":"Niu","year":"1999","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-005-1580-1","article-title":"Targeting STAT3 affects melanoma on multiple fronts","volume":"24","author":"Kortylewski","year":"2005","journal-title":"Cancer Metastasis Rev."},{"issue":"20","key":"10.1016\/j.ejmech.2019.111885_bib9","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1038\/sj.onc.1207383","article-title":"Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis","volume":"23","author":"Xie","year":"2004","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ejmech.2019.111885_bib10","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/onc.2013.45","article-title":"Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor","volume":"33","author":"Becker","year":"2014","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.ejmech.2019.111885_bib11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ejmech.2019.111885_bib12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"Flaherty","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2019.111885_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2019.111885_bib14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2019.111885_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2018.06.038","article-title":"IL6\/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells","volume":"433","author":"Notarangelo","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/ml100010j","article-title":"Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors","volume":"1","author":"Chen","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2019.111885_bib17","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1021\/jm2000882","article-title":"Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3","volume":"54","author":"Mandal","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.111885_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/jid.2010.255","article-title":"Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor","volume":"131","author":"Miyoshi","year":"2011","journal-title":"J.\u00a0Investig. Dermatol."},{"issue":"8","key":"10.1016\/j.ejmech.2019.111885_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/13543784.2017.1351941","article-title":"Do STAT3 inhibitors have potential in the future for cancer therapy?","volume":"26","author":"Wong","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"13","key":"10.1016\/j.ejmech.2019.111885_bib20","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1073\/pnas.0409894102","article-title":"A\u00a0low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells","volume":"102","author":"Song","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2019.111885_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2012.12.046","article-title":"Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents","volume":"62","author":"Duan","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2019.111885_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10528-015-9691-z","article-title":"Evaluation of the effect of 1,3-bis(4-phenyl)-1H-1,2,3-Triazolyl-2-Propanolol on gene expression levels of JAK2-STAT3, NF-kappaB, and SOCS3 in cells cultured from biopsies of mammary lesions","volume":"53","author":"Becerril","year":"2015","journal-title":"Biochem. Genet."},{"issue":"20","key":"10.1016\/j.ejmech.2019.111885_bib23","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1016\/j.bmc.2011.08.063","article-title":"Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors","volume":"19","author":"Hou","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2019.111885_bib24","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1016\/j.bmc.2016.08.008","article-title":"The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3","volume":"24","author":"Lee","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2019.111885_bib25","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b01672","article-title":"Nitric oxide donor-based cancer therapy: advances and prospects","volume":"60","author":"Huang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejmech.2013.01.023","article-title":"Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy","volume":"62","author":"Chen","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2019.111885_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1021\/ml1000273","article-title":"Identification of a new series of STAT3 inhibitors by virtual screening","volume":"1","author":"Matsuno","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"6689","key":"10.1016\/j.ejmech.2019.111885_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/28101","article-title":"Three-dimensional structure of the Stat3beta homodimer bound to DNA","volume":"394","author":"Becker","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.111885_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.freeradbiomed.2008.03.020","article-title":"The chemical biology of nitric oxide: implications in cellular signaling","volume":"45","author":"Thomas","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2019.111885_bib31","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/0008-5472.CAN-12-3175","article-title":"A\u00a0novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2019.111885_bib32","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-10-3852","article-title":"6-Bromoindirubin-3\u2019-oxime inhibits JAK\/STAT3 signaling and induces apoptosis of human melanoma cells","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2019.111885_bib33","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.6b01489","article-title":"Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking","volume":"60","author":"Yu","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.111885_bib34","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/acschembio.7b00341","article-title":"Selective inhibition of STAT3 phosphorylation using a nuclear-targeted kinase inhibitor","volume":"12","author":"Bartolowits","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.111885_bib35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ejmech.2018.03.053","article-title":"Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors","volume":"151","author":"Guo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2018.10.067","article-title":"A\u00a0novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3)","volume":"162","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib37","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ejmech.2018.08.037","article-title":"Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis","volume":"157","author":"Huang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2019.111885_bib38","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood-2013-02-484196","article-title":"STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation","volume":"124","author":"Gough","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejmech.2019.111885_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1021\/cb700186x","article-title":"Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target","volume":"2","author":"Timofeeva","year":"2007","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2019.111885_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.990080101","article-title":"A\u00a0pragmatic approach to the analysis of DNA histograms with a definable G1 peak","volume":"8","author":"Watson","year":"1987","journal-title":"Cytometry"},{"issue":"3","key":"10.1016\/j.ejmech.2019.111885_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1593\/neo.07971","article-title":"Inhibition of JAK1, 2\/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells","volume":"10","author":"Xiong","year":"2008","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Lee","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2019.111885_bib43","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1038\/s41467-019-12996-8","article-title":"Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in\u00a0vivo","volume":"10","author":"Kaoud","year":"2019","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jhet.5570450251","article-title":"Microwave-assisted d\u00f6bner synthesis of 2-phenylquinoline-4-carboxylic acids and their antiparasitic activities","volume":"45","author":"Muscia","year":"2008","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bioorg.2014.12.003","article-title":"Synthesis, molecular docking and anti-inflammatory screening of novel quinoline incorporated pyrazole derivatives using the Pfitzinger reaction II","volume":"58","author":"El-Feky","year":"2015","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib46","first-page":"273","article-title":"Derivatives of 2-phenyl quinoline, Part I. Preparation of some \"atophans\" from ventric aldehyde","volume":"66","author":"Trikojus","year":"1932","journal-title":"J.\u00a0Proc. R. Soc. N. S. W."},{"issue":"2","key":"10.1016\/j.ejmech.2019.111885_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11243-007-9038-7","article-title":"Synthesis, characterization, and DNA-binding properties of copper(II), cobalt(II), and nickel(II) complexes with salicylaldehyde 2-phenylquinoline-4-carboylhydrazone","volume":"33","author":"Xu","year":"2008","journal-title":"Transit. Met. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib48","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1039\/c39840001320","article-title":"Aromatic annelation by reaction of arylimidoyl radicals with alkynes: a new synthesis of quinolines","volume":"20","author":"Leardini","year":"1984","journal-title":"J.\u00a0Chem. Soc., Chem. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2019.111885_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11094-011-0613-z","article-title":"Synthesis and antiviral activity of several quinoline derivatives","volume":"45","author":"Zemtsova","year":"2011","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.ejmech.2019.111885_bib50","article-title":"Quinoline-4-carboxylic acid derivatives and their use as color formers","author":"Raulfs","year":"1990","journal-title":"Eur. Pat. Appl."},{"issue":"13","key":"10.1016\/j.ejmech.2019.111885_bib51","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1080\/00958970902773833","article-title":"Synthesis, characterization, and DNA-binding of Ln(III) complexes with 2-hydroxybenzylidene-2-phenylquinoline-4-carbonylhydrazone","volume":"62","author":"Xu","year":"2009","journal-title":"J.\u00a0Coord. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2019.111885_bib52","doi-asserted-by":"crossref","first-page":"8675","DOI":"10.1016\/j.bmc.2006.08.022","article-title":"Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents","volume":"14","author":"Metwally","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bioorg.2017.09.018","article-title":"Novel quinoline incorporating 1,2,4-triazole\/oxime hybrids: synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations","volume":"75","author":"Mohassab","year":"2017","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2019.111885_bib54","first-page":"90","article-title":"Efficient synthesis, characterization and biological evaluation of some new atophan carbohydrazide derivatives","volume":"6","author":"El-Aal","year":"2014","journal-title":"J.\u00a0Chem. Pharm. Res."},{"issue":"20","key":"10.1016\/j.ejmech.2019.111885_bib55","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1021\/jm070564e","article-title":"Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus","volume":"50","author":"Xie","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111885_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bioorg.2016.09.005","article-title":"Novel 1,3,4-oxadiazole\/oxime hybrids: synthesis, docking studies and investigation of anti-inflammatory, ulcerogenic liability and analgesic activities","volume":"69","author":"Abd-Ellah","year":"2016","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.111885_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/ml300129b","article-title":"From in silico discovery to intra-cellular activity: targeting JNK-protein interactions with small molecules","volume":"3","author":"Kaoud","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2019.111885_bib58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/s30800276","article-title":"Measurement of nitric oxide production in biological systems by using griess reaction assay","volume":"3","author":"Sun","year":"2003","journal-title":"Sensors"},{"issue":"9","key":"10.1016\/j.ejmech.2019.111885_bib59","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-14-2087","article-title":"Histone deacetylase inhibitors repress tumoral expression of the proinvasive factor RUNX2","volume":"75","author":"Sancisi","year":"2015","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.ejmech.2019.111885_bib60","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"issue":"Web Server issue","key":"10.1016\/j.ejmech.2019.111885_bib61","doi-asserted-by":"crossref","first-page":"W665","DOI":"10.1093\/nar\/gkh381","article-title":"PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations","volume":"32","author":"Dolinsky","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"10.1016\/j.ejmech.2019.111885_bib62","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1073\/pnas.181342398","article-title":"Electrostatics of nanosystems: application to microtubules and the ribosome","volume":"98","author":"Baker","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.ejmech.2019.111885_bib63","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"Chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:01:34Z","timestamp":1759327294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419310372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":63,"alternative-id":["S0223523419310372"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111885","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111885"}}